Morten Ladekarl

overlæge

Morten Ladekarl

overlæge

  • Institut for Klinisk Medicin - Kræftafdelingen
  • Onkologisk Afdeling D, NBG
Postaddresse:
Nørrebrogade 44
8000
Aarhus C
Postaddresse:
Århus Sygehus;Nørrebrogade 44
8000
Århus C

E-mail: mortlade@rm.dk

Mobil: 61399326

Telefon: 89492654, 78462654

Fødselsår

1962

Uddannelser

2002Specialist i onkologi, Department of Oncology, Aarhus Universitetshospital and Aalborg Universitetshospital, Danmark
1989MD, Eksperimentel Klinisk Onkologi, Aarhus Universitet, Danmark

Akademiske grader

1998Dr.med

Forskningsområder

Kvantitative evalueringer af kræftstrukturer i væv, incl. inflammation
Kræftinflammation, kræft og prognoser
Eksperimentel kræftbehandling
Kliniske forsøg på patienter med større gastrointestinale svulster, hepatocellulare kræftsvulster, neuroendocrine svulster og ukendt primær kræft
Sjældne kræftsvulster

Nuværende ansættelse

2013-Overlæge, onkologi, Klinisk Institut for Onkologi, Afdeling D, Aarhus Universitetshospital, Danmark

Tidligere ansættelser

2007Overlæge, Aarhus Universitetshospital, Danmark
2005Overlæge, Onkologisk afdeling, Aarhus Universitetshospital, Danmark
2003-2005Embedslæge, Onkologisk afdeling, Aarhus Universitetshospital, Aarhus, Danmark
1996-2003Reservelæge, Onkologisk afdeling, Aarhus Universitetshospital og Aalborg Universitetshospital, Danmark
1995-1996Reservelæge, Patologisk Institut, Regionshospitalet Randers, Danmark
1991-1995Forsker, Stereotaktisk Forsknings Laboratorium, Kræftens Bekæmpelse, Aarhus Universitetshospital, Danmark
1989-1991Reservelæge i adskillige afdelinger: Regionshospitalet Randers, Aarhus Universitetshopital og Regionshospitalet Vest, Danmark

Publikationer og repræsentationer

Publikationer: 36, Peer-reviewed artikler: 35, H-index: 8, Citations: 302, Præsentationer ved videnskabelige møder (oral): ?

Udvalgs- og bestyrelsesposter

Medlem af tre Danske tværfaglige grupper for, henholdsvis, bugspytkirtel- og leverkræft samt gastro-esophageale svulster
Tidligere formand og sekretær for Scandinavian Network for Hepatocellular Carcinomainoma
Medlem af the National Board of Health committee (RADS) for treatment of neuroendocrine tumors
Medlem af the National Board of Health committee for follow-up of patients with upper gastro-intestinal tumors
Member of the Nordic Network for Neuroendocrine Tumors

Vejledning

Vejleder for 3 ph.d.-studenter
2 complette og 1 igangværende

Priser og udmærkelser

Kræftens Bekæmpelse
Thaysen Foundation
Colind Foundation
Foersom Foundation
King Christian X Foundation
Fonden til lægevidenskabens fremme
Novo Foundation
Yde Foundation
Schølin Foundation
Kopp Foundation
Danielsen Foundation

Organisering af møder

2 årlige møder i Scandinavian Network for Hepatocellular Carcinoma
3 årlige møder i Sector for Clinical Research i Onkologisk afdeling, Aarhus

Involvering i videnskabelige tidsskrifter

>44 oral and poster presentations at national and international meetings
38 scientific articles

Publikationer

Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer

Ladekarl, M., Rasmussen, L. S., Kirkegård, J., Chen, I., Pfeiffer, P., Weber, B., Skuladottir, H., Østerlind, K., Larsen, J. S., Mortensen, F. V., Engberg, H., Møller, H. & Fristrup, C. W., mar. 2022, I: Acta Oncologica. 61, 3, s. 277-285 9 s.

Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer

Steiniche, T., Rha, S. Y., Chung, H. C., Georgsen, J. B., Ladekarl, M., Nordsmark, M., Jespersen, M. L., Kim, H. S., Kim, H., Fein, C., Tang, L. H., Wu, T., Marton, M. J., Peter, S., Kelsen, D. P. & Ku, G., dec. 2021, I: Cancer Medicine. 10, 23, s. 8365-8376 12 s.

Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy

Mouritzen, M. T., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A. C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L., Frary, J. M. C., Drivsholm, L. B., Vesteghem, C., Christensen, H. S., Bjørnhart, B. & Pøhl, M., okt. 2021, I: Cancers. 13, 19, 13 s., 4846.

Clinically decisive (dis)agreement in multidisciplinary team assessment of esophageal squamous cell carcinoma; a prospective, national, multicenter study

Achiam, M. P., Nordsmark, M., Ladekarl, M., Olsen, A., Loft, A., Garbyal, R. S., Larsen, M. H., Ainsworth, A. P., Kristensen, T. S., Dikinis, S., Kjær, D. W., Bæksgaard, L., Siemsen, M., Nielsen, M. B., Schlander, S., Kramer, S., Katballe, N., Kruhlikava, I., Tabaksblat, E., Fisker, R. V., Mortensen, P. B., Holtved, E., Eckardt, J., Detlefsen, S., Naujokaite, G. & Lütken, C. D., sep. 2021, I: Acta Oncologica. 60, 9, s. 1091-1099 9 s.

Merkelcellekarcinom

Naseri, S., Steiniche, T., Ladekarl, M., Hölmich, L. R., Langer, S. W., Tabaksblat, E., Junker, N. & Chakera, A. H., jul. 2021, I: Ugeskrift for Læger. 183, 30, 9 s., V03210260.

Patterns of Palliative Chemotherapy and Survival in Patients with Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study

Rasmussen, L. S., Fristrup, C. W., Jensen, B. V., Pfeiffer, P., Weber, B., Yilmaz, M. K., Poulsen, L., Ladekarl, M., Østerlind, K., Larsen, J. S., Skuladottir, H., Bøgsted, M. & Falkmer, U. G., maj 2021, I: Pancreas. 50, 5, s. 685-695 11 s.

Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms

Pommergaard, H. C., Nielsen, K., Sorbye, H., Federspiel, B., Tabaksblat, E. M., Vestermark, L. W., Janson, E. T., Hansen, C. P., Ladekarl, M., Garresori, H., Hjortland, G. O., Sundlöv, A., Galleberg, R., Knigge, P., Kjaer, A., Langer, S. W. & Knigge, U., maj 2021, I: Journal of Neuroendocrinology. 33, 5, 12 s., e12967.

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

Ali, A. S., Langer, S. W., Federspiel, B., Hjortland, G. O., Grønbæk, H., Ladekarl, M., Welin, S., Weber Vestermark, L., Arola, J., Osterlund, P., Knigge, U., Sørbye, H., Micke, P., Grimelius, L., Grönberg, M. & Tiensuu Janson, E., dec. 2020, I: PLOS ONE. 15, 12, 12 s., e0243900.

International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

Díaz-González, Á., Sanduzzi-Zamparelli, M., da Fonseca, L. G., Di Costanzo, G. G., Alves, R., Iavarone, M., Leal, C., Sacco, R., Matilla, A. M., Hernández-Guerra, M., Aballay Soteras, G., Wörns, M. A., Pinter, M., Varela, M., Ladekarl, M., Chagas, A. L., Mínguez, B., Arenas, J. I., Granito, A., Sánchez-Torrijos, Y., Rojas, Á., Rodríguez de Lope, C., Alvares-da-Silva, M. R., Pascual, S., Rimassa, L., Lledó, J. L., Huertas, C., Sangro, B., Giannini, E. G., Delgado, M., Vergara, M., Perelló, C., Lue, A., Sala, M., Gallego, A., Coll, S., Hernáez, T., Piñero, F., Pereira, G., França, A., Marín, J., Anders, M., Mello, V., Lozano, M., Nault, J. C., Menéndez, J., García Juárez, I., Bruix, J. & Reig, M., jun. 2020, I: Liver International. 40, 6, s. 1467-1476 10 s.

Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis

Kirkegård, J., Gaber, C., Lund, J. L., Hinton, S. P., Ladekarl, M., Heide-Jørgensen, U., Cronin-Fenton, D. & Mortensen, F. V., feb. 2020, I: Cancer epidemiology. 64, 9 s., 101647.

Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study

Rasmussen, L. S., Fristrup, C. W., Jensen, B. V., Pfeiffer, P., Weber, B., Yilmaz, M. K., Poulsen, L. Ø., Ladekarl, M., Østerlind, K., Larsen, J. S., Skuladottir, H., Hansen, C. P., Mortensen, M. B., Mortensen, F. V., Sall, M., Detlefsen, S., Bøgsted, M. & Falkmer, U. G., 2020, I: European Journal of Cancer. 129, s. 50-59 10 s.

Tumor ulceration, reduced infiltration of CD8-lymphocytes, high neutrophil-to-CD8-lymphocyte ratio and absence of MC virus are negative prognostic markers for patients with merkel cell carcinoma

Naseri, S., Steiniche, T., Georgsen, J. B., Thomsen, R., Ladekarl, M., Heje, M., Damsgaard, T. E. & Bønnelykke-Behrndtz, M. L., 2020, I: Cancers. 12, 4, 11 s., 888.

The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study

Skau Rasmussen, L., Vittrup, B., Ladekarl, M., Pfeiffer, P., Karen Yilmaz, M., Østergaard Poulsen, L., Østerlind, K., Palnæs Hansen, C., Bau Mortensen, M., Viborg Mortensen, F., Sall, M., Detlefsen, S., Bøgsted, M. & Wilki Fristrup, C., jun. 2019, I: Acta Oncologica. 58, 6, s. 864-871 8 s.

Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature

Overby, A., Duval, L., Ladekarl, M., Laursen, B. E. & Donskov, F., feb. 2019, I: Clinical Genitourinary Cancer. 17, 1, s. e32-e37 6 s.

Urban versus Rural Residency and Pancreatic Cancer Survival: A Danish Nationwide Population-based Cohort Study

Kirkegård, J., Ladekarl, M., Fristrup, C. W., Hansen, C. P., Sall, M. & Mortensen, F. V., 16 aug. 2018, I: PLOS ONE. 13, 8

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Ali, A. S., Grönberg, M., Langer, S. W., Ladekarl, M., Hjortland, G. O., Vestermark, L. W., Österlund, P., Welin, S., Grønbæk, H., Knigge, U., Sorbye, H. & Janson, E. T., 6 mar. 2018, I: Medical Oncology. 35, 4, s. 47

Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study

Madsen, A. H., Ladekarl, M., Villadsen, G. E., Grønbæk, H., Sørensen, M. M., Stribolt, K., Verwaal, V. J. & Iversen, L. H., feb. 2018, I: Annals of Surgical Oncology. 25, 2, s. 422-430 9 s.

Association of PD-L1 expression with prognosis among patients with 10 select cancers

Steiniche, T., Ladekarl, M., Bæhr Georgsen, J., Andreasen, S., Busch-Sørensen, M., Zhou, W., Pruitt, S. K., Joe, A. K. & Liaw, K-L., 2018, I: Annals of Oncology. 29, s. viii15

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas

Galleberg, R. B., Knigge, U., Tiensuu Janson, E., Vestermark, L. W., Haugvik, S-P., Ladekarl, M., Langer, S. W., Grønbæk, H., Österlund, P., Hjortland, G. O., Assmus, J., Tang, L., Perren, A. & Sorbye, H., sep. 2017, I: European Journal of Surgical Oncology. 43, 9, s. 1682-1689 8 s.

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

Ali, A. S., Grönberg, M., Federspiel, B., Scoazec, J-Y., Hjortland, G. O., Grønbæk, H., Ladekarl, M., Langer, S. W., Welin, S., Vestermark, L. W., Arola, J., Österlund, P., Knigge, U., Sorbye, H., Grimelius, L. & Janson, E. T., 2017, I: P L o S One. 12, 11, 15 s., e0187667.

BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping

Sharma, M. B., Carus, A., Sunde, L., Hamilton-Dutoit, S. & Ladekarl, M., 2016, I: Acta Oncologica. s. 1-5 5 s.

A Nationwide Retrospective Study of Perioperative Chemotherapy for Gastroesophageal Adenocarcinoma: Tolerability, Outcome, and Prognostic Factors

Larsen, A. C., Holländer, C., Duval, L., Schønnemann, K., Achiam, M., Pfeiffer, P., Yilmaz, M. K., Thorlacius-Ussing, O., Bæksgaard, L. & Ladekarl, M., maj 2015, I: Annals of Surgical Oncology. 22, 5, s. 1540-1547 8 s.

Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients

Olsen, I. H., Holt, N., Langer, S. W., Hasselby, J. P., Grønbæk, H., Hillingsø, J., Mahmoud, M., Ladekarl, M., Iversen, L. H., Kjær, A., Federspiel, B. H. & Knigge, U., 2015, I: PLOS ONE. 10, 2, s. e0117627

Postoperative but not preoperative treatment with sorafenib inhibits liver regeneration in rats

Andersen, K. J., Knudsen, A. R., Kannerup, A-S., Nyengaard, J. R., Hamilton-Dutoit, S., Ladekarl, M. & Mortensen, F. V., 15 apr. 2014, I: The Journal of surgical research.

Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer

Kræmer, P. C., Schmidt, H. H. & Ladekarl, M., apr. 2014, I: Danish Medical Journal. 61, 4, 4 s., A4819.

Strong Prognostic Value of Tumor-infiltrating Neutrophils and Lymphocytes Assessed by Automated Digital Image Analysis in Early Stage Cervical Cancer: A Comparator Study with Observer-assisted Stereological Assessments

Carus, A., Donskov, F., Nielsen, P. S., Hager, H., Nedergaard, B., Steiniche, T. & Ladekarl, M., 2014, I: Journal of OncoPathology. 2, 2, s. 1-9 9 s.

Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia

Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H. & Donskov, F., 15 aug. 2013, I: Journal of Translational Medicine. 11, 8, 10 s., 189.

Advanced hepatocellular carcinoma in adolescence associated with congenital cholestasis: A case description

Ladekarl, M., Villadsen, G. E., Rudbeck, A. R., Aagenæs, Ø., Nielsen, J. E., Hamilton-Dutoit, S. & Nordsmark, M., 1 jan. 2013, I: Case Reports in Oncology. 6, 1, s. 98-103 6 s.

Diffuse abdominal splenosis mimicking peritoneal metastases in a 35-year-old man with a resectable carcinoma of the ampulla of vater

Sorensen, S. F., Mortensen, F. V., Hellberg, Y. & Ladekarl, M., 2013, I: Case Reports in Oncology. 6, 3, s. 467-71 5 s.

Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability

Køstner, A. H., Sørensen, M., Olesen, R. K., Grønbæk, H., Lassen, U. & Ladekarl, M., 2013, I: Scientific World Journal. 2013, s. 931972

Sorafenib inhibits liver regeneration in rats

Andersen, K. J., Knudsen, A. R., Kannerup, A-S., Sasanuma, H., Nyengaard, J. R., Hamilton-Dutoit, S., Ladekarl, M. & Mortensen, F. V., 2013, I: H P B. 15, 12, s. 944-950 7 s.

Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome

Carus, A., Ladekarl, M., Hager, H., Pilegaard, H., Nielsen, P. S. & Donskov, F., 2013, I: Lung Cancer. 81, 1, s. 130-7 8 s.

Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer

Carus, A., Ladekarl, M., Hager, H., Nedergaard, B. & Donskov, F., 2013, I: B J C. 108, 10, s. 2116-22 7 s.

Dansk Pancreas Cancer Database

Fristrup, C., Palnæs Hansen, C., Ladekarl, M. & Mortensen, M. B., 2012, I: Ugeskrift for Læger. 174, 42, s. 2545 1 s.

Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

Rohrberg, K. S., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Pappot, H., Christensen, I. J., Høyer-Hansen, G., Sørensen, M., Skov, B. G., Buysschaert, I., Carmeliet, P. & Lassen, U., 2012, I: Acta Oncologica. Supplement. 51, 2, s. 234-42 9 s.

Malignant pheochromocytoma and paraganglioma: Three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs

Zukauskaite, R., Hjorthgau, K., Poulsen, P. L., Baerentzen, S. & Ladekarl, M., 30 jun. 2011, I: Acta Oncologica. 50, 8, s. 1255-9 5 s.

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

Rohrberg, K. S., Pappot, H., Lassen, U., Westman, M., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Sørensen, M., Christensen, I. J. & Skov, B. G., 2011, I: Cancer Biology & Therapy. 11, 8, s. 732-9 8 s.

Ovariemetastaser fra ventrikelcancer diagnosticeret med diffusionsvægtet 3T-magnetisk resonans-skanning

Røhl, L., Nellemann, H. M., Ladekarl, M. & Pedersen, E. M., 2011, I: Ugeskrift for Laeger. 173, 16-17, s. 1212-3 2 s.

Onkologisk behandling af patienter med pancreascancer

Ladekarl, M., Jensen, B. V. & Pfeiffer, P., 3 maj 2010, I: Ugeskrift for Laeger. 172, 18, s. 1373-6 4 s.

A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years

Nedergaard, B., Ladekarl, M., Nyengaard, J. R. & Nielsen, K., 2008, I: Gynecologic Oncology. 108, 1, s. 106-111 6 s.

Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer

Nedergaard, B. S., Ladekarl, M., Thomsen, H. F., Nyengaard, J. R. & Nielsen, K., 2007, I: British Journal of Cancer. 97, 8, s. 1135-8 3 s.

Stereologic estimation of the total numbers, the composition and the anatomic distribution of lymphocytes in cone biopsies from patients with stage I squamous cell carcinoma of the cervix uteri

Nedergaard, B., Nielsen, K., Nyengaard, J. R. & Ladekarl, M., 2007, I: Acta Pathologica Microbiologica et Immunologica Scandinavica. 115, 12, s. 1321-30 9 s.

Detection of circulating tumour lysate-reactive CD4+ T cells in melanoma patients

Ladekarl, M., Agger, R., Fleischer, C. C., Hokland, M., Hulgaard, E. F., Kirkin, A., von der Maase, H., Petersen, M. S., Rytter, C., Zeuthen, J. & Gundersen, H. J. G., 2004, I: Cancer Immunology, Immunotherapy. 53, s. 560-566 7 s.

Measurements of hypoxia using pimonidazole and polarograhpic oxygen-sensitive electrodes in human cervix carcinomas

Nordsmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S-C., Ladekarl, M., Havsteen, H., Lindegaard, J. C., Davidson, S. E., Varia, M., West, C., Hunter, R., Overgaard, J. & Raleigh, J. A., apr. 2003, I: Radiotherapy & Oncology. 67, 1, s. 35-44 10 s.

Nye behandlingsperspektiver ved duktalt carcinoma in situ mammae

Ladekarl, M., Grau, C. & Andersen, J., 10 sep. 2001, I: Ugeskrift for Laeger. 163, 37, s. 5014-7 4 s.

Nye behandlingsperspektiver ved duktalt carcinoma in situ mammae: New therapeutic perspectives in breast ductal carcinoma in situ

Ladekarl, M., Grau, C. & Andersen, J., 2001, I: Ugeskrift for Laeger. 163, 37, s. 5014-5017 4 s., 4979.

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

Horsman, M. R., Ehrnrooth, E., Ladekarl, M. & Overgaard, J., 1 nov. 1998, I: International Journal of Radiation Oncology, Biology, Physics. 42, 4, s. 895-898 4 s.

Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas

Jensen, V., Sørensen, F. B., Bentzen, S. M., Ladekarl, M., Nielsen, O. S., Keller, J. & Jensen, O. M., jun. 1998, I: Histopathology. 32, 6, s. 536-46 11 s.

The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer

Jensen, V., Ladekarl, M., Holm-Nielsen, P., Melsen, F. & Sørensen, F. B., aug. 1995, I: Journal of Pathology. 176, 4, s. 343-352 10 s.

Quantitative histopathological variables in in situ and invasive ductal and lobular carcinomas of the breast

Ladekarl, M. & Sørensen, F. B., dec. 1993, I: APMIS Supplementum. 101, 12, s. 895-903 9 s.

Prognostic, quantitative histopathologic variables in lobular carcinoma of the breast

Ladekarl, M. & Sørensen, F. B., 1 nov. 1993, I: Cancer. 72, 9, s. 2602-2611 10 s.

Prognostic value of nucleolar size and size pleomorphism in choroidal melanomas

Sørensen, F. B., Gamel, J. W., Jensen, O. A., Ladekarl, M. & McCurdy, J., maj 1993, I: APMIS Supplementum. 101, 5, s. 358-368 11 s.